Ali Urman

Ali Urman, ARK Analyst, joins the discussion on the breakthrough in Crispr gene editing. The podcast also covers Google's Gemini and Twitter's Grok, as well as the approval of America's first gene-editing therapy, Casgevy. They explore the differences between gene editing and gene therapy, debate the controversy surrounding Gemini's marketing, and discuss the value accrual in new technology.

Sam Korus, Nick Grous, Brett Winton, and Ali Urman discuss Sam Altman's plan to raise $7 trillion for an AI chip. They explore the exponential growth of AI, the impact of quantum, recreation, and AlphaGo, and the high drug prices in the US compared to other countries. They also analyze the viability of Mark Cuban's generics company and discuss the impact of drug pricing on affordability and access to care.